A flexible and coherent test/estimation procedure based on restricted mean survival times for censored time-to-event data in randomized clinical trials

Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards

(2017) Hakim-Moulay Dehbi et al.   BMJ-British Medical Journal

Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards

(2017) Hakim-Moulay Dehbi et al.   BMJ-British Medical Journal

The ASA's Statement onp-Values: Context, Process, and Purpose

(2016) Ronald L. Wasserstein et al.   AMERICAN STATISTICIAN

Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated

(2016) Patrick Royston et al.   BMC Medical Research Methodology

Restricted Mean Survival Time: An Obligatory End Point for Time-to-Event Analysis in Cancer Trials?

(2016) Roger P. A’Hern   JOURNAL OF CLINICAL ONCOLOGY

Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials

(2016) Ludovic Trinquart et al.   JOURNAL OF CLINICAL ONCOLOGY

The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical Trials

(2016) Julien Péron et al.   JAMA Oncology

Describing Differences in Survival Curves

(2016) Rick Chappell et al.   JAMA Oncology

Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies

(2015) Hajime Uno et al.   ANNALS OF INTERNAL MEDICINE

On the restricted mean survival time curve in survival analysis

(2015) Lihui Zhao et al.   BIOMETRICS

A versatile test for equality of two survival functions based on weighted differences of Kaplan-Meier curves

(2015) Hajime Uno et al.   STATISTICS IN MEDICINE

Tests for comparing estimated survival functions

(2014) C. Chauvel et al.   BIOMETRIKA

Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis

(2014) Hajime Uno et al.   JOURNAL OF CLINICAL ONCOLOGY

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

(2014) Hansjochen Wilke et al.   LANCET ONCOLOGY

Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome

(2013) Patrick Royston et al.   BMC Medical Research Methodology

Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves

(2012) Patricia Guyot et al.   BMC Medical Research Methodology

The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt

(2011) Patrick Royston et al.   STATISTICS IN MEDICINE

Improved Logrank-Type Tests for Survival Data Using Adaptive Weights

(2009) Song Yang et al.   BIOMETRICS

Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group

(2008) Robert J. Paridaens et al.   JOURNAL OF CLINICAL ONCOLOGY